Search for: "Sandoz, Inc"
Results 361 - 380
of 679
Sort by Relevance
|
Sort by Date
14 Nov 2013, 7:48 pm
Sandoz Inc., No. 12-654-GMS-MPT (D. [read post]
10 Nov 2013, 9:03 pm
Sandoz, Inc. 1:13-cv-07776; filed November 1, 2013 in the Southern District of New York • Plaintiffs: Purdue Pharma L.P.; P.F. [read post]
31 Oct 2013, 5:26 am
Sandoz, Inc., 723 F.3d1363, 1372 (Fed. [read post]
13 Sep 2013, 6:49 pm
Sandoz, Inc., No. 2012-1567, -1568, 1569, -1570 (Fed. [read post]
3 Sep 2013, 7:21 pm
In Therasense, Inc. vs. [read post]
29 Aug 2013, 12:22 pm
Sandoz, Inc., 544 F.3d 1341, 1367 (Fed.Cir. 2008) (citing Mikohn Gaming Corp. v. [read post]
22 Aug 2013, 1:34 pm
Loryna, a generic version of YAZ, and Syeda, a generic version of Yasmin, are made and sold by Sandoz, Inc. [read post]
19 Aug 2013, 3:52 pm
Sandoz where the patent was invalidated:"There is extensive evidence in the prior art showing the concomitant administration of brimonidine and timolor multiple times per day, that the combination had benefits over the administration of either alone, and that there was a motivation to combine the two achieve better patient compliance." [read post]
7 Aug 2013, 11:00 pm
Sandoz, Inc., the Federal Circuit invalidated a number of claims directed to a polymer... [read post]
29 Jul 2013, 9:26 pm
Sandoz, Inc. [read post]
5 Jul 2013, 5:00 am
Squibb and Sons, Inc. v. [read post]
10 Jun 2013, 9:53 am
Sandoz, Inc., 566 F.3d 1282 (Fed. [read post]
2 Jun 2013, 8:40 pm
• Defendant: Sandoz Inc. [read post]
17 May 2013, 9:09 am
Sandoz Inc., C.A. [read post]
7 May 2013, 1:00 am
In Allergan, Inc. v. [read post]
6 May 2013, 4:33 pm
On May 1, the US Court of Appeals for the Federal Circuit issued an interesting, yet controversial, ruling in Allergan Inc. v Sandoz Inc. et Al., examining obviousness in the context of a combination ophthalmic drug treatment. [read post]
2 May 2013, 1:34 pm
Sandoz Inc. [read post]
1 May 2013, 9:59 pm
Sandoz that a claimed method for treating glaucoma (which differed from the three-times-a-day dosage regimens required of the individual components) was not inherently obvious, and thereby prevented a group of generic challengers from being able to market their own versions of Combigan® before the expiration of the patent containing the claimed method. [read post]
4 Apr 2013, 1:34 pm
Sandoz, Inc., Civil Action 17 3:11-cv-03080-MLC-LHG (Complaint filed: 26 May 2011). [read post]
21 Mar 2013, 3:07 pm
Sandoz, Inc., C.A. [read post]
